Shares of Personalis (NASDAQ:PSNL) dropped 8% during mid-day trading on Monday . The company traded as low as $17.58 and last traded at $17.78, approximately 506,901 shares changed hands during mid-day trading. A decline of 0% from the average daily volume of 507,665 shares. The stock had previously closed at $19.33.

PSNL has been the subject of a number of recent research reports. CIBC restated a “hold” rating on shares of Sandstorm Gold in a research note on Monday, July 15th. Oppenheimer set a $110.00 price objective on shares of Medtronic and gave the company a “buy” rating in a research note on Monday, July 15th. Bank of America set a $68.00 price objective on shares of Inphi and gave the company a “buy” rating in a research note on Monday, July 15th. Cowen restated a “buy” rating on shares of Avrobio in a research note on Monday, July 15th. Finally, Morgan Stanley set a $70.00 target price on shares of Edison International and gave the stock a “hold” rating in a report on Monday, July 15th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $28.25.

In other news, Director Ken Ludlum bought 70,000 shares of the stock in a transaction dated Monday, June 24th. The shares were acquired at an average price of $17.00 per share, with a total value of $1,190,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

A hedge fund recently bought a new stake in Personalis stock. SG Americas Securities LLC bought a new position in Personalis (NASDAQ:PSNL) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 8,395 shares of the company’s stock, valued at approximately $228,000. Institutional investors own 0.01% of the company’s stock.

About Personalis (NASDAQ:PSNL)

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Featured Story: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.